Elsevier

Survey of Ophthalmology

Volume 65, Issue 5, September–October 2020, Pages 513-529
Survey of Ophthalmology

Major review
Diabetic keratopathy: Insights and challenges

https://doi.org/10.1016/j.survophthal.2020.02.005Get rights and content

Abstract

Ocular complications from diabetes mellitus are common. Diabetic keratopathy, the most frequent clinical condition affecting the human cornea, is a potentially sight-threatening condition caused mostly by epithelial disturbances that are of clinical and research attention because of their severity. Diabetic keratopathy exhibits several clinical manifestations, including persistent corneal epithelial erosion, superficial punctate keratopathy, delayed epithelial regeneration, and decreased corneal sensitivity, that may lead to compromised visual acuity or permanent vision loss. The limited amount of clinical studies makes it difficult to fully understand the pathobiology of diabetic keratopathy. Effective therapeutic approaches are elusive. We summarize the clinical manifestations of diabetic keratopathy and discuss available treatments and up-to-date research studies in an attempt to provide a thorough overview of the disorder.

Introduction

Diabetes mellitus (DM) is one of the most common deadly metabolic disease worldwide. The incidence rate of DM has risen over the years and is expected to double by the year 2030.147 The steep increase of the diabetic population is thought to be mainly due to the changes in lifestyle that results in elevated calorie intake and obesity. Increase in the diabetic population has led to significant financial and clinical burdens and spurs demands for effective clinical treatments.147

DM develops when the pancreas fails to synthesize enough insulin or the body becomes resistant to insulin, or both, leading to high levels of blood glucose. The three main types are type 1 diabetes mellitus (type 1DM), type 2DM, and gestational DM (characterized in Table 1). DM is correlated with a number of complications accounting for increased disability, morbidity, and mortality.209 Acute metabolic complications associated with a high mortality rate and abnormally high blood glucose concentrations (hyperglycemia) include ketoacidosis. On the other hand, extremely low blood glucose concentrations (hypoglycemia) can lead to coma. Chronic uncontrolled DM may lead to devastating consequences in the form of long-term vascular complications.97 The hyperglycemic condition during DM has various implications on various tissues, and the most common complications witnessed during such conditions are retinopathy, nephropathy, neuropathy, and keratopathy.11,169,171

DM is known to cause structural and functional alterations to the human cornea. The cornea is a clear, highly organized, external layer of the eye responsible for letting in and focusing light. It has three distinct layers separated by acellular membranes. The outermost layer is the epithelium (Fig. 1), responsible for protecting the eye against various foreign particles and providing protection to the other internal structures of the eye. Below the epithelium is a tough condensed layer known as the Bowman layer (Fig. 1). The Bowman layer is acellular and composed of collagen fibers difficult to penetrate, protecting the cornea from any deeper injury. The next and the thickest layer of the cornea is the stroma (Fig. 1), which provides the cornea its structure and elastic form and is also responsible for the corneal transparency. The fourth layer lying below the stroma is the Descemet membrane (Fig. 1), a thin elastic layer of the cornea that protects the cornea against various infections. The fifth and the most posterior layer of the cornea is the neuroepithelial layer, commonly referred to as the endothelium (Fig. 1), responsible for keeping the cornea clear by controlling the hydration of the cornea. The endothelium is a single layer of hexagonal cells approximately 5 micrometers in thickness.37 All the different layers of the cornea have their own unique functions and together support the normal functioning of the eye.

Section snippets

Clinical relevance

Diabetic keratopathy or diabetic corneal epitheliopathy204,216 is a degenerative corneal disease seen in patients suffering from systemic DM.49 Diabetes prevalence among adults aged between 20 and 99 years in a 2017 International Diabetes Federation census was approximately 451 million worldwide. This number is expected to increase to 693 million by the year 204533 and, with approximately 46–64% of diabetic patients acquiring diabetic keratopathy,170 this is a disease that requires serious

Clinical manifestation

The prevalence of DM has risen exponentially over the last three decades, with a resultant increase in morbidity and mortality mainly from its complications. The most common clinical manifestations are discussed in the following sections.

Available treatments

Standard treatments for diabetic keratopathy include the use of topical lubricants,65,92,117 topical antibiotic ointments,18,41,45,50,66,117,196,210,213 patching, bandage soft contact lenses (BSCLs),51,66 tarsorrhaphy, and corneal transplants.214 None of these methods are greatly effective, even when used in combination, especially for type 1DM, as they do not address the problem of delayed corneal healing secondary to DM.1,107,124 Diabetic keratopathy, brought on by any form of DM, is

Current research approaches and models

As DM is a highly heterogeneous disease, care must be taken when choosing a model to study diabetic complications, including those in the cornea. Many diabetic models, both in vitro and in vivo, can be/currently are being used for the study of diabetic keratopathy.24 Applications of the models discussed in the following sections span the research field from metabolic, physiological, genetic, epigenetic, and therapeutic. It is important to note that none of these models fully recapitulate the

Gene therapy

Multiple growth factors that show promise to treat diabetic keratopathy include insulin, opioid growth factor, NGF, and substance P.215 Nonetheless, the inhibitory growth factor (plasma Met-enkephalins) is known to be elevated in people with diabetes.219 Corneal Met-enkephalins are blocked by topical naltrexone, simultaneously leading to corneal reepithelialization via increasing DNA synthesis of the corneal epithelium. Previous findings show that diabetic keratopathy is reversed by naltrexone

Conclusions

Diabetic keratopathy is a significant clinical problem with no truly effective treatment available. The large number of studies published in the field, combined with the absence of a medical treatment, highlight the complexity of the disease. Focus on developing animal models for DM is certainly justified, although we are still looking for an accurate, more translational diabetic keratopathy model. As a result of anatomical differences between the mouse/rat and the human cornea, we may need to

Methods of literature search

There were no specific exclusion/inclusion criteria for our literature search. Published work written in other languages were analyzed by abstract, only, which is usually available in English language. Searches included terms similar to “diabetic keratopathy,” “corneal injury treatment,” and “corneal biomechanics.” All articles found relevant to this article upon review were included upon the authors' discretion. Online applications used for the searches were PubMed database and //clinicaltrials.gov

References (222)

  • A. Gautieri et al.

    Advanced glycation end-products: mechanics of aged collagen from molecule to tissue

    Matrix Biol

    (2017)
  • Y. Goldich et al.

    Effect of diabetes mellitus on biomechanical parameters of the cornea

    J Cataract Refract Surg

    (2009)
  • P. Hamrah et al.

    Corneal sensation and subbasal nerve alterations in patients with herpes simplex keratitis: an in vivo confocal microscopy study

    Ophthalmology

    (2010)
  • J. He et al.

    Mapping the nerve architecture of diabetic human corneas

    Ophthalmology

    (2012)
  • J. He et al.

    Mapping the entire human corneal nerve architecture

    Exp Eye Res

    (2010)
  • M.F. Hulbert

    Efficacy of eyepad in corneal healing after corneal foreign body removal

    Lancet

    (1991)
  • K. Inoue et al.

    The corneal endothelium and thickness in type II diabetes mellitus

    Jpn J Ophthalmol

    (2002)
  • P. Jud et al.

    Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: a review

    Diabetes Res Clin Pract

    (2019)
  • A. Kabosova et al.

    Human diabetic corneas preserve wound healing, basement membrane, integrin and MMP-10 differences from normal corneas in organ culture

    Exp Eye Res

    (2003)
  • P.K. Kaiser

    A comparison of pressure patching versus no patching for corneal abrasions due to trauma or foreign body removal. Corneal Abrasion Patching Study Group

    Ophthalmology

    (1995)
  • H. Abdelkader et al.

    New therapeutic approaches in the treatment of diabetic keratopathy: a review

    Clin Exp Ophthalmol

    (2011)
  • M.A. Ahad et al.

    Randomized controlled study of ocular lubrication versus bandage contact lens in the primary treatment of recurrent corneal erosion syndrome

    Cornea

    (2013)
  • Y. Akimoto et al.

    Elevated expression of O-GlcNAc-modified proteins and O-GlcNAc transferase in corneas of diabetic Goto-Kakizaki rats

    Invest Ophthalmol Vis Sci

    (2003)
  • A. Al-Awar et al.

    Experimental diabetes mellitus in different animal models

    J Diabetes Res

    (2016)
  • L. Aloe et al.

    Nerve growth factor: a focus on neuroscience and therapy

    Curr Neuropharmacol

    (2015)
  • J.D. Arbour et al.

    Should we patch corneal erosions?

    Arch Ophthalmol

    (1997)
  • A. Bansal et al.

    DNA methylation and its role in the pathogenesis of diabetes

    Pediatr Diabetes

    (2017)
  • J.K. Bardsley et al.

    Overview of diabetes

    Crit Care Nurs Q

    (2004)
  • A. Barsegian et al.

    Corneal neuropathy: an underrated manifestation of diabetes mellitus

    J Clin Endocrinol Diabetes

    (2018)
  • S. Bekmez et al.

    Higher intraocular pressure levels associated with lower hysteresis in type 2 diabetes

    Open Ophthalmol J

    (2018)
  • J.M. Benitez-Del-Castillo et al.

    Treatment of recurrent corneal erosion with substance P-derived peptide and insulin-like growth factor I

    Arch Ophthalmol

    (2005)
  • H. Bennie et al.

    Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects (NTX-PED-001)

    (2010)
  • S. Bi et al.

    Obesity in the Otsuka long evans tokushima fatty rat: mechanisms and discoveries

    Front Nutr

    (2016)
  • G. Bikbova et al.

    Diabetic corneal neuropathy: clinical perspectives

    Clin Ophthalmol (Auckland, NZ)

    (2018)
  • G. Boberg-Ans et al.

    Comparison of Fucithalmic viscous eye drops and chloramphenicol eye ointment as a single treatment in corneal abrasion

    Acta Ophthalmol Scand

    (1998)
  • N.B. Boggild-Madsen et al.

    Comparison of eye protection with methylcellulose an paraffin ointments during general anaesthesia

    Can Anaesthetists' Soc J

    (1981)
  • E. Bonafonte-Márquez et al.

    Epidermal Growth Factor Receptor (EGFR) in corneal damage: update and new insights from recent reports

    Cutan Ocul Toxicol

    (2011)
  • D. Brasacchio et al.

    Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail

    Diabetes

    (2009)
  • S.M. Brown et al.

    Neurotrophic and anhidrotic keratopathy treated with substance P and insulin-like growth factor 1

    Arch Ophthalmol

    (1997)
  • Y. Bu et al.

    Experimental modeling of cornea wound healing in diabetes: clinical applications and beyond

    BMJ open Diabetes Res Care

    (2019)
  • S. Burman et al.

    Cultivated limbal stem cell transplantation for ocular surface reconstruction

    Clin Ophthalmol (Auckland, NZ)

    (2008)
  • N. Busted et al.

    Clinical observations on the corneal thickness and the corneal endothelium in diabetes mellitus

    Br J Ophthalmol

    (1981)
  • K. Chakrabarty et al.

    Corneal cell therapy: with iPSCs, it is no more a far-sight

    Stem Cel Res Ther

    (2018)
  • H.-F. Chen et al.

    Persistent corneal epithelial defect after pars plana vitrectomy

    Retina

    (2016)
  • Z. Chen et al.

    Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort

    Proc Natl Acad Sci U S A

    (2016)
  • N. Chikamoto et al.

    Efficacy of substance P and insulin-like growth factor-1 peptides for preventing postsurgical superficial punctate keratopathy in diabetic patients

    Jpn J Ophthalmol

    (2009)
  • S. Culina et al.

    Mechanisms in endocrinology: insulin and type 1 diabetes: immune connections

    Eur J Endocrinol

    (2013)
  • T. Dayeh et al.

    Genome-wide DNA methylation analysis of human pancreatic islets from type 2 diabetic and non-diabetic donors identifies candidate genes that influence insulin secretion

    PLoS Genet

    (2014)
  • M.A. Del Buey et al.

    An update on corneal biomechanics and architecture in diabetes

    J Ophthalmol

    (2019)
  • R.S. Dhuria et al.

    Current status and patent prospective of animal models in diabetic research

    Adv Biomed Res

    (2015)
  • Cited by (77)

    • Pharmaceutical applications of chitosan in skin regeneration: A review

      2024, International Journal of Biological Macromolecules
    View all citing articles on Scopus

    Funding: This work was supported by the National Institutes of Health (EY028949).

    Competing interest statement: The authors have no competing interests.

    These authors contributed equally.

    View full text